title: Antinociceptive, antiedematogenic and antiangiogenic effects of benzaldehyde semicarbazone.
abstract: Semicarbazones induce an anticonvulsant effect in different experimental models. As some anticonvulsant drugs also have anti-inflammatory activity, the effects of benzaldehyde semicarbazone (BS) on models of nociception, edema and angiogenesis were investigated. BS (10, 25 or 50 mg/kg, i.p.) markedly inhibited the second phase of nociceptive response induced by formaldehyde (0.34%, 20 microl) in mice, but only the highest dose inhibited the first phase of this response. The thermal hyperalgesia and mechanical allodynia induced by carrageenan (1%, 50 microl, i.pl.) in rats were also inhibited by BS (50 mg/kg, i.p.). However, treatment of mice with BS did not induce an antinociceptive effect in the hot-plate model. The paw edema induced by carrageenan (1%, 50 microl, i.pl.) in rats was inhibited by BS (25 or 50 mg/kg, i.p.). Treatment of mice with BS (0.25, 0.5 or 2.5 mg/kg/day, i.p., 7 days) also inhibited angiogenesis induced by subcutaneous implantation of a sponge disc. It is unlikely that the antinociceptive effect induced by BS results from motor incoordination or a muscle relaxing effect, as the mice treated with this drug displayed no behavioral impairment in the rotarod apparatus. In conclusion, we demonstrated that BS presents antinociceptive, antiedematogenic and antiangiogenic activities. An extensive investigation of the pharmacological actions of BS and its derivatives is justified and may lead to the development of new clinically useful drugs.
authors.affiliation: Faculdade de Farmácia, Universidade Federal de Minas Gerais, Avenida Antônio Carlos 6627, 31270-901, Belo Horizonte, MG, Brazil.
authors.forename: Leonardo Tadeu S
authors.initials: LT
authors.lastname: Rocha
authors.forename: Karina A
authors.initials: KA
authors.lastname: Costa
authors.forename: Antônio Carlos P
authors.initials: AC
authors.lastname: Oliveira
authors.forename: Elias B
authors.initials: EB
authors.lastname: Nascimento
authors.forename: Caryne M
authors.initials: CM
authors.lastname: Bertollo
authors.forename: Fernanda
authors.initials: F
authors.lastname: Araújo
authors.forename: Letícia R
authors.initials: LR
authors.lastname: Teixeira
authors.forename: Sílvia P
authors.initials: SP
authors.lastname: Andrade
authors.forename: Heloisa
authors.initials: H
authors.lastname: Beraldo
authors.forename: Márcio M
authors.initials: MM
authors.lastname: Coelho
mesh_terms: D000818:Animals; D001547:Benzaldehydes / Q000737:chemistry / Q000494:pharmacology*; D002351:Carrageenan / Q000494:pharmacology; D004487:Edema / Q000188:drug therapy*; D005557:Formaldehyde / Q000494:pharmacology; D006930:Hyperalgesia / Q000188:drug therapy; D008297:Male; D051379:Mice; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D009619:Nociceptors / Q000187:drug effects / Q000378:metabolism; D010146:Pain / Q000188:drug therapy*; D051381:Rats; D017208:Rats, Wistar; D045442:Rotarod Performance Test; D012664:Semicarbazones / Q000737:chemistry / Q000494:pharmacology*; D013997:Time Factors
chemical_list: D001547:Benzaldehydes; D012664:Semicarbazones; C512112:benzaldehyde semicarbazone; D005557:Formaldehyde; D002351:Carrageenan; C032175:benzaldehyde